Prophylactic Sclerotherapy of Large Esophageal Varices

William C. Santangelo, Maria I. Dueno, Boyce L. Estes, Guenter J. Krejs

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

We randomly assigned 95 patients with large esophageal varices (Grade 3 or 4) who had not previously had upper gastrointestinal tract bleeding to two groups: 49 received intravariceal sclerotherapy, and 46 were followed as controls. Over a mean follow-up of 13 months there was no difference between the sclerotherapy group and the control group in mortality (24.4 percent) or any significant difference in average hospital stay per month (3.0 vs. 2.6 days). Sclerotherapy was associated with significantly more episodes of upper gastrointestinal bleeding (26 vs. 10 episodes, P<0.05); 75 percent of deaths in the sclerotherapy group were related to bleeding, as compared with 18 percent in the control group. An additional 54 patients with cirrhosis who did not qualify for the study were also followed — 20 with small varices and 34 with none. Mortality was 20 and 15 percent, respectively; no deaths were due to bleeding. We conclude that prophylactic sclerotherapy does not provide clinical benefit to patients with large esophageal varices. (N Engl J Med 1988; 318:814–8.)

Original languageEnglish (US)
Pages (from-to)814-818
Number of pages5
JournalNew England Journal of Medicine
Volume318
Issue number13
DOIs
StatePublished - Mar 31 1988

Fingerprint

Sclerotherapy
Esophageal and Gastric Varices
Hemorrhage
Control Groups
Upper Gastrointestinal Tract
Mortality
Varicose Veins
Length of Stay
Fibrosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Santangelo, W. C., Dueno, M. I., Estes, B. L., & Krejs, G. J. (1988). Prophylactic Sclerotherapy of Large Esophageal Varices. New England Journal of Medicine, 318(13), 814-818. https://doi.org/10.1056/NEJM198803313181304

Prophylactic Sclerotherapy of Large Esophageal Varices. / Santangelo, William C.; Dueno, Maria I.; Estes, Boyce L.; Krejs, Guenter J.

In: New England Journal of Medicine, Vol. 318, No. 13, 31.03.1988, p. 814-818.

Research output: Contribution to journalArticle

Santangelo, WC, Dueno, MI, Estes, BL & Krejs, GJ 1988, 'Prophylactic Sclerotherapy of Large Esophageal Varices', New England Journal of Medicine, vol. 318, no. 13, pp. 814-818. https://doi.org/10.1056/NEJM198803313181304
Santangelo, William C. ; Dueno, Maria I. ; Estes, Boyce L. ; Krejs, Guenter J. / Prophylactic Sclerotherapy of Large Esophageal Varices. In: New England Journal of Medicine. 1988 ; Vol. 318, No. 13. pp. 814-818.
@article{1578b52fd8e046aab60d81334e381451,
title = "Prophylactic Sclerotherapy of Large Esophageal Varices",
abstract = "We randomly assigned 95 patients with large esophageal varices (Grade 3 or 4) who had not previously had upper gastrointestinal tract bleeding to two groups: 49 received intravariceal sclerotherapy, and 46 were followed as controls. Over a mean follow-up of 13 months there was no difference between the sclerotherapy group and the control group in mortality (24.4 percent) or any significant difference in average hospital stay per month (3.0 vs. 2.6 days). Sclerotherapy was associated with significantly more episodes of upper gastrointestinal bleeding (26 vs. 10 episodes, P<0.05); 75 percent of deaths in the sclerotherapy group were related to bleeding, as compared with 18 percent in the control group. An additional 54 patients with cirrhosis who did not qualify for the study were also followed — 20 with small varices and 34 with none. Mortality was 20 and 15 percent, respectively; no deaths were due to bleeding. We conclude that prophylactic sclerotherapy does not provide clinical benefit to patients with large esophageal varices. (N Engl J Med 1988; 318:814–8.)",
author = "Santangelo, {William C.} and Dueno, {Maria I.} and Estes, {Boyce L.} and Krejs, {Guenter J.}",
year = "1988",
month = "3",
day = "31",
doi = "10.1056/NEJM198803313181304",
language = "English (US)",
volume = "318",
pages = "814--818",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - Prophylactic Sclerotherapy of Large Esophageal Varices

AU - Santangelo, William C.

AU - Dueno, Maria I.

AU - Estes, Boyce L.

AU - Krejs, Guenter J.

PY - 1988/3/31

Y1 - 1988/3/31

N2 - We randomly assigned 95 patients with large esophageal varices (Grade 3 or 4) who had not previously had upper gastrointestinal tract bleeding to two groups: 49 received intravariceal sclerotherapy, and 46 were followed as controls. Over a mean follow-up of 13 months there was no difference between the sclerotherapy group and the control group in mortality (24.4 percent) or any significant difference in average hospital stay per month (3.0 vs. 2.6 days). Sclerotherapy was associated with significantly more episodes of upper gastrointestinal bleeding (26 vs. 10 episodes, P<0.05); 75 percent of deaths in the sclerotherapy group were related to bleeding, as compared with 18 percent in the control group. An additional 54 patients with cirrhosis who did not qualify for the study were also followed — 20 with small varices and 34 with none. Mortality was 20 and 15 percent, respectively; no deaths were due to bleeding. We conclude that prophylactic sclerotherapy does not provide clinical benefit to patients with large esophageal varices. (N Engl J Med 1988; 318:814–8.)

AB - We randomly assigned 95 patients with large esophageal varices (Grade 3 or 4) who had not previously had upper gastrointestinal tract bleeding to two groups: 49 received intravariceal sclerotherapy, and 46 were followed as controls. Over a mean follow-up of 13 months there was no difference between the sclerotherapy group and the control group in mortality (24.4 percent) or any significant difference in average hospital stay per month (3.0 vs. 2.6 days). Sclerotherapy was associated with significantly more episodes of upper gastrointestinal bleeding (26 vs. 10 episodes, P<0.05); 75 percent of deaths in the sclerotherapy group were related to bleeding, as compared with 18 percent in the control group. An additional 54 patients with cirrhosis who did not qualify for the study were also followed — 20 with small varices and 34 with none. Mortality was 20 and 15 percent, respectively; no deaths were due to bleeding. We conclude that prophylactic sclerotherapy does not provide clinical benefit to patients with large esophageal varices. (N Engl J Med 1988; 318:814–8.)

UR - http://www.scopus.com/inward/record.url?scp=0023857705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023857705&partnerID=8YFLogxK

U2 - 10.1056/NEJM198803313181304

DO - 10.1056/NEJM198803313181304

M3 - Article

C2 - 3281001

AN - SCOPUS:0023857705

VL - 318

SP - 814

EP - 818

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -